Braj Yatra in Mathura Vrindaban: Mathura Vrindavan Temple Tour

Braj Yatra in Mathura Vrindaban: Mathura Vrindavan Temple Tour

The 4th Protein Discovery and Therapeutics

The Annual Protein Discovery and Therapeutics conference will take place on October 19-21, 2011 in at Paradise Point Resort & Spa in San Diego, CA. It will enable the discussion of how antibody and alternative protein therapeutics provide the pharmaceutical industry with solutions to conditions and diseases beyond what small molecule drug discovery can offer. The conference will also delve into how this promise and potential come with a large price tag, and will discuss novel targets and methods, alternatives to conventional antibody engineering, regulations and patent law. These discussions are conducted in an intimate setting that allows for networking and interaction among attendees and speakers at the conference.

Topics that will be covered at the conference include The Future of Protein Discovery, which will delve into bi-specific and multi-specific fusion proteins, modified proteins and antibodies, antibody drug conjugates, biosimilars and biosuperiors. Also covered at the conference will be Novel Alternative Protien Therapeutics, such as non-IG scaffolds, antibody fragments, new peptide approaches in pharmacotherapeutic development, and nutraceuticals. Overcoming Challenges in Protein Therapeutics will touch upon the steps in the discovery process: advances in expression systems, immunogenicity, aggregation, subvisible particles, stability, and delivery. The final step, patenting a protein therapeutic, will be addressed in a featured presentation by Susan Alpert Seigel and William D. Noonan of Klarquist Sparkman LLP.

The plenary keynote session features J. Carmel Egan, Vice President of Eli Lilly and Company, William R. Strohl, Vice President at Johnson and Johnson, Barry A. Morgan, Vice President at GlaxoSmithKline, Martin Edwards, Vice Presdient at Pfizer Global Research and Development, and Glenn D. Prestwich, President Professor at University of Utah. Some of the companies represented include Novartis, Roche Diagnostics GmbH, Zyngenia, Micromet AG, Anaptysbio, Nektar Therapeutics, NovImmune SA, Ambrx, Affibody, RC Tech and Merus Biopharmaceuticals. Academic and government organizations, such as the National Center Institute, Scripps Research Institute and Albany Medical College will also be represented.

The topics to be covered at the conference are Vaccines for Infectious diseases, including Dengue vaccines, HIV vaccines, Mucosal vaccines, and Malaria Vaccines. Therapeutic Vaccines will cover cancer vaccines and Alzheimer’s vaccines. Regulatory and Government Policy will cover U.S. National Vaccine Plan, government regulations, and animal rule. New Technologies in Vaccine Development will cover adjuvants, MIMIC, synthetic VLPs, among others. The conference will also address the Future Trends of Vaccine Discovery and New Vaccines, which will delve into Nisseria and nanoparticles.

A World Summit on Central nervous system disease

Affected by millions of people worldwide, CNS diseases have continued to be one of the major challenges faced by researches and experts in the industry, academia and government affiliations. Fortunately, recent years has shown much progress in drug discovery efforts, especially in the CNS fields of neuropsychiatry, behavioral neurology, Alzheimer’s, Parkinson’s, Huntington’s, multiple sclerosis, stroke, dementia, depression, schizophrenia and much more. The increased access to imaging and analytic techniques has enabled the development of novel on- and off-label treatment options, which are emerging on a near-monthly basis. Experts are also working on various novel therapeutics and approaches such as biomarkers, stem cell therapy, protein misfolding and aggregation, immunotherapy, vaccines for Alzheimer's, BACE inhibitors and much more. Also, there has been rapid growth in the use of deep brain stimulation (DBS), non-invasive transcranial magnetic stimulation (TMS), mGluR’s, allosteric modulators, treatment refractory disorders, fragile X, among others.

GTC's CNS Diseases World Summit, which will take place on September 22-23, 2011 in San Francisco, CA, gives global biotechnology and pharmaceutical companies, as well as leading experts in the field an opportunity to learn about relevant CNS Disease drug discovery efforts that will affect the industry, network with high-level executives from top pharma and various biotech/pharmaceutical companies and explore potential collaborations. The intimate setting of GTC conferences enables such interaction and networking, by bringing together speakers and attendees, by allowing the exchange of different ideas, and allowing the variety of perspectives at a given topic, whether it be from a pharmaceutical, academic, or governmental stand point. The summit consists of three concurrent tracks. Those tracks are Advances in Neuropsychiatric Treatment, Neurodegenerative Conditions Research and Development, and CNS Partnering and Deal-making. By registering for a summit, an attendee has the ability to attend all three tracks. Registering for a summit enables one to pick and choose the talks he most wishes to hear, and to attend each track whenever his desired talk is scheduled to commence. Students and post-docs are also encouraged to attend. They can register for a discounted rate.